MAIA Biotechnology Inc. (MAIA)
NYSE: MAIAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MAIA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $68.54M
- EPS (TTM)
- -$0.47
- Dividend yield
- None
- 52-week range
- 0.895 – 3.19
- Day range
- 1.08 – 1.15
- Volume / Avg
- 498.73K / 524.29K
- Beta
- —
- Shares outstanding
- 61.75M
52-week range
MAIA stock today
On Nov 20, MAIA ended the session at $1.11, shedding $0.03 (2.63%), versus the S&P 500's 3.70% decline. At this level, MAIA sits near the bottom of its 52-week range of $0.895 to $3.19: 65.2% below the high, set on Jan 28, 2026 and 24.0% above the low. MAIA is down 27.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.7%.
MAIA Biotechnology has posted a net loss over the last twelve months (EPS of -$0.47), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MAIA Biotechnology
Company profileMAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vlad Vitoc M.B.A., M.D.
- Headquarters
- Chicago, IL
- Employees
- 13
- IPO year
- 2022
- Website
- maiabiotech.com
Financial highlights
Full financialsMAIA Biotechnology reported a net loss of $22.4 million, compared with a loss of $23.3 million a year earlier. Diluted earnings per share came in at -$0.70.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — |
| Growth | — | — | — | — | — |
| Net income | $-22.40M | $-23.25M | $-19.77M | $-15.77M | $-12.58M |
| EPS (diluted) | $-0.70 | $-1.05 | $-1.49 | $-1.75 | $-2.37 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$12.00+981.08%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.12 vs $-0.13
- Surprise
- +7.69%
MAIA news
All MAIA news- MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung CancerNasdaq
- MAIA Biotechnology Reports 88% Disease Control Rate In Expanded Phase 2 NSCLC StudyNasdaqMAIA, CFR
- MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung CancerGlobeNewswire
- Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key GoalNasdaqABBV, AZN, CMMB, GMAB
MAIA Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| COYACoya Therapeutics Inc. | 2.95 | -1.01% | $69.20M | vs MAIA |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs MAIA |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs MAIA |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.48 | -2.63% | $70.14M | vs MAIA |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs MAIA |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs MAIA |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs MAIA |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs MAIA |
Indexes, lists and sector
MAIA Biotechnology stock FAQ
What is MAIA Biotechnology's stock price today?
MAIA last traded at $1.11 as of Nov 20, 4:00 PM EST, down 2.63% on the day. Prices are delayed at least 15 minutes.
Who is MAIA Biotechnology's CEO?
Dr. Vlad Vitoc M.B.A., M.D. is the chief executive officer of MAIA Biotechnology Inc., which has about 13 employees.
What is the MAIA 52-week high?
The 52-week high for MAIA is $3.19 and the 52-week low is $0.895. The stock is currently 65.2% below its high.